Teva Pharmaceutical Industries Limited Stock Price
- 3 Narratives written by author
- 2 Comments on narratives written by author
- 126 Fair Values set on narratives written by author
TEVA Community Narratives
Analyst Commentary Highlights Modest Price Target Increase and Positive Outlook for Teva Pharmaceutical Industries
Late Stage Pipeline And Margin Expansion Will Transform This Pharma Into A Future Cash Engine
Late Stage Pipeline And Biosimilar Pressure Will Constrain Long Term Earnings Power
Analyst Commentary Highlights Modest Price Target Increase and Positive Outlook for Teva Pharmaceutical Industries
View narrativeLate Stage Pipeline And Biosimilar Pressure Will Constrain Long Term Earnings Power
View narrativeLate Stage Pipeline And Margin Expansion Will Transform This Pharma Into A Future Cash Engine
View narrativeTrending Discussion
No trending discussion available.
Recently Updated Narratives
TEVA: Celiac And Vitiligo Data Are Expected To Drive Neuroscience Pivot
TEVA: Fairly Valued Outlook Will Weigh Vitiligo Data And Biosimilar Expansion
TEVA: Vitiligo Readout And Neuroscience Expansion Are Expected To Drive Upside
Snowflake Analysis
Teva Pharmaceutical Industries Limited Key Details
About TEVA
- Founded
- 1901
- Employees
- 32008
- CEO
- Website
View website
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin’s lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington’s disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.